To our knowledge, our results could be a preliminary experience that revealed the negative correlation between SGLT2 inhibitors utilization and consecutive cervical cancer occurrence in patients with T2DM clinically. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.